Targets › FCER2
2 programs from 2 companies in 5 trials: 3 Phase 3, 2 Phase 2; Neurology; next expected readout Dec 2026.
Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B cells. (UniProt, P06734)
Open in Phaseline: the race on FCER2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dianthus Therapeutics | Claseprubart complement C5 inhibitor | FCER2, COMP | Phase 3 | Myasthenia Gravis, Generalized; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy | Dec 2026 |
| AstraZeneca | gefurulimab CD23 antagonist monoclonal antibody | FCER2 | Phase 3 | Generalized Myasthenia Gravis | Dec 2026 |
Myasthenia Gravis, Generalized (2) Chronic Inflammatory Demyelinating Polyneuropathy (1) Multifocal Motor Neuropathy (1) Generalized Myasthenia Gravis (1)
antibody (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.